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Two studies in the current issue of Immunity (Pratama et al., 2013; Vogel et al., 2013) demonstrate that the
RNA-binding proteins Roquin-1 and Roquin-2 have redundant function in the posttranscriptional repression
of Icos messenger RNA by CD4+ T cells.CD4+ follicular helper T (Tfh) cells promote
maturation of B cells into memory or anti-
body-secreting plasma cells in germinal
centers (GCs) of secondary lymphoid
organs (SLOs) (Craft, 2012). Similarly,
autoantibodies in diseases such as sys-
temic lupus erythematosus (SLE, or lupus)
are produced via GC B cells, with
dysfunctional Tfh cells necessary for their
development (Vinuesa et al., 2009). Two
papers in this issue of Immunity provide
new insights into the regulation of Tfh
cell help for GC B cells and how this reg-
ulatory pathway might be subverted in
autoimmune conditions such as lupus
(Pratama et al., 2013; Vogel et al., 2013).
For naive CD4+ T cells fated to the Tfh
developmental pathway, antigen priming
by dendritic cells (DCs) in T cell zones of
SLOs results in upregulation of the induc-
ible costimulator (ICOS). ICOS signaling,
delivered by ICOS ligand (ICOS-L) ex-
pressed on T-zone DCs, is required for
development and expansion of Tfh cells
and expression of their canonical tran-
scription factor Bcl6 (Choi et al., 2011).ICOS, a member of the CD28-superfamily
of costimulatory molecules, is upregu-
lated by T cells upon activation, unlike
its constitutively expressed sister mole-
cule CD28 (Linterman et al., 2009). The
Icos gene originated through duplication
of the Cd28 locus, making the differential
expression of their protein products a
curiosity. CD28 provides the crucial sec-
ond step in T cell activation upon binding
its cognate ligands CD80 and CD86,
upregulated on DCs following recognition
of microbial products. Unlike CD28
ligands, however, ICOS-L is constitutively
present on DCs; consequentially, induc-
ible ICOS expression imparts regulation
of T cell activation and subsequent Tfh
cell induction. The RNA-binding protein
Roquin-1, a RING (really interesting new
gene)-domain containing product of the
Rc3h1 gene, posttranscriptionally regu-
lates Icosmessenger RNA (mRNA), main-
taining activation-induced expression of
ICOS in CD4+ T cells (Vinuesa et al.,
2005) (Figure 1). Recognition of the 30
untranslated region of this mRNA by theRNA-binding domain of Roquin-1 facili-
tates degradation of the transcript
through interactions with the decapping
enzyme Edc4 and helicase Rck (Glas-
macher et al., 2010). Roquin expression
is repressed upon activation of CD4+
T cells via degradation of the Rc3h1 tran-
script by the miR-223 microRNA (miRNA),
allowing for the regulated expression of
target transcripts.
Previous studies by Vinuesa and col-
leagues identified a role for the Roquin
protein in mRNA regulation by using
mice with a single-base substitution in
the Rc3h1 locus, leading to alterations in
Roquin structure and activity (Vinuesa
et al., 2005). Animals with homozygosity
of themutant allele,Rc3h1san/san or sanro-
que, had ICOS overexpression on CD4+
T cells, a consequence of the mutant
Roquin protein, with Bcl6 upregulation
and Tfh cell expansion upon immuniza-
tion, leading to robust GCs and plasma
cells producing isotype-switched anti-
bodies and a lupus-like phenotype (Fig-
ure 1). Roquin-1 localized to cytosolic
Figure 1. Roquin-1 and Roquin-2 Redundantly Suppress Icos mRNA Expression in CD4+ T
Cells
In wild-type CD4+ T cells, Roquin-1 binds target mRNAs in stress granules, promoting their degradation
via RNA decay proteins Edc4 and Rck. Rc3h1san/san (sanroque) mice express a mutant Roquin-1 protein
that binds mRNA, yet lacks the capacity to promote its degradation, while preventing the accumulation of
Roquin-2 in the stress granules and subsequent compensatory repression of target transcripts, including
Icos. Overexpression of ICOS in sanroque mice leads to an accumulation of Tfh cells and robust GC
responses, with systemic autoimmunity. In mice lacking Roquin-1, Roquin-2 redundantly suppresses
Icos mRNA, preventing Tfh cell expansion. By contrast, mice lacking Roquin-1 and Roquin-2 fail to sup-
press Icos expression, phenocopying the sanroque strain.
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RNA binding zinc-finger, suggested
involvement of the protein in mRNA
regulation.
In later work, mice with targeted dele-
tion of exon 2 of the Rc3h1 gene in CD4+
T cells had impaired Roquin-1 expression
(Bertossi et al., 2011); however, unlike
sanroque animals, these mice lacked Tfh
cell expansion and autoimmunity (Fig-
ure 1). This phenotypic discrepancy
prompted two groups reporting in this
issue of Immunity (Pratama et al., 2013;
Vogel et al., 2013) to characterize the
role of Roquin-2, a protein with close
sequence homology to Roquin-1, as
possibly redundant in posttranscriptional
mRNA binding and repression. Roquin-2,
encoded by the Rc3h2 gene, shares the
RNA-binding zinc finger and the RING-
finger domains of Roquin-1. As with
Roquin-1-deficient mice, Roquin-2 null
animals lacked a striking phenotype
upon immunization. However, Roquin-1
and Roquin-2 double-deficient animals
developed expansion of Tfh cells and
GCs with autoimmunity, by contrastto the single gene-deficient controls
(Figure 1). These results phenocopy san-
roque mice and confirm the redundant
function of Roquin-1 and Roquin-2 in
regulating ICOS expression in Tfh cells.
A major difference between the autoim-
mune-prone sanroque and disease-free
Roquin-1 null mice was localization of
the mutant Roquin protein in the former
animals to RNA granules and binding
Icos transcripts therein via its functioning
RING domain. In Roquin-1 null mice,
Roquin-2 localizes to cytosolic RNA
stress granules and acts as a compen-
sating RNA-binding and mRNA-regu-
lating protein. By contrast, the structural
change in the sanroque Roquin-1 inhibits
its mRNA suppressive capability, filling
what the authors term a binding ‘‘niche’’
whereby the mutant Roquin-1 binds
target mRNAs preventing Roquin-2 medi-
ated compensatory regulation.
Vogel et al. explored a second role for
Roquin in the regulation of Ox40 mRNA.
In Roquin-1 and Roquin-2 double-defi-
cient mice, OX40 expression, and subse-
quent NF-kB pathway activation wasImmunityenhanced in CD4+ T cells. The authors
suggest that altered expression of this
coreceptor contributes to an increase in
expression of IRF4, which along with
Bcl6, is a transcription factor required for
Tfh cell development; hence, regulation
of Ox40 mRNA expression might provide
a second axis for adaptive control by
Roquin-1 and Roquin-2.
Paralogs of the mammalian Roquin
genes are present in species that evolved
prior to those with adaptive immune
systems. Pratama et al. investigated the
role of Roquin in nonlymphoid cells,
finding that tumor necrosis factor-a
(TNF-a) expression was increased in san-
roque macrophages, with heightened
inflammation in an arthritis model attrib-
uted to inadequate steady-state Roquin-
mediated TNF-a suppression. These
results highlight a role for Roquin in innate
immunity, suggesting that it can limit
inflammation in diseases such as rheuma-
toid arthritis.
Both papers suggest a select set of
Roquin targets; however, it will be impor-
tant to detail the full map of Roquin-
binding partners, a data set potentially
useful in addressing the role of Roquin
in innate immunity. Considering the
multiple targets of Roquin in CD4+
T cells, it is possible that genes apart
from Tnf will fall under its regulation.
Both papers also suggest that ICOS is
the primary driver of the Tfh cell expan-
sion in the sanroque and Roquin-1 and
Roquin-2 double-deficient mice. Howev-
er, Vogel et al. propose a role for Roquin
in the regulation of Ox40 mRNA expres-
sion and subsequent NF-kB signaling
and IRF4 expression in Tfh cells. It will
be important to further dissect this
pathway and critically demonstrate Ox40
regulation by Roquin-1 and Roquin-2.
Studies to parse the effects of Roquin on
IRF4 expression should offer a fuller
understanding of the abnormal Tfh cell
phenotype in Roquin-deficient animals.
Finally, both papers highlight the role
of Roquin in autoimmunity and discuss
the therapeutic potential of targeting
the Roquin regulatory axis. Searching
for SNPs in the Rc3h1 and Rc3h2 genes
of SLE patients will help assess the role
of the Roquin in disease. Furthermore,
the regulation of Rc3h1 transcript ex-
pression by miR-223 offers therapuetic
potential as the targets of this miRNA
are dissected.38, April 18, 2013 ª2013 Elsevier Inc. 625
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In this issue of Immunity, Ma et al. (2013) demonstrate that neoplastic cell release of ATP drives recruitment
and differentiation of CD11b+ dendritic cells within tumors, where their ability to locally present antigen
improves response to anthracycline-based chemotherapy.The majority of cancer patients are
treated with chemotherapy (CTX) at
some stage of their disease. Ostensibly
targeting proliferating neoplastic cells,
chemotherapeutics also profoundly affect
immune cells that, at least in part, also
regulate therapeutic efficacy (Zitvogel
et al., 2011). Although chemotherapeutics
can induce transient lymphopenia and
other systemic changes, certain classes
such as anthracyclines are known to
induce immunogenic cell death (ICD)
and are dependent on intratumoral CD8+
T cells for efficacy in some murine tumor
models, with clinical data also supporting
this association (Zitvogel et al., 2011).
Much of themolecular underpinnings of
CTX-induced ICD have been delineated
through a series of studies by the Zitvogel
and Kroemer groups. Collectively, studies
from these researchers indicate that ICD
requires pericellular exposure of calreticu-
lin to promote engulfment by antigen-pre-
senting cells (APCs), release of unmodi-
fied high-mobility group box 1 (HMGB1)
and ATP, and subsequent induction of
dendritic cell (DC) activation by binding
to Toll-like receptor 4 (TLR4) and the puri-
nergic receptor P2RX7, respectively.
Presumably, activated Batf3-dependent
CD103+ DCs then migrate to draininglymph nodes and activate antigen-spe-
cific CD8+ T cells, leading to enhanced
CD8+ T cell infiltration approximately
7 days after CTX (Ma et al., 2011). How-
ever, also observed in subcutaneous
murine tumor models is secretion of inter-
leukin-1b (IL-1b) by DCs and recruitment
of IL-17A expressing gd T cells, both of
whicharecritical for response toanthracy-
clines (Ma et al., 2011), thus indicating an
important role for the tumormicroenviron-
ment in mediating CTX response. Now,
Zitvogel and Ma extend upon their previ-
ous studies and investigate antigen pre-
sentation following anthracyline therapy,
revealing local presentation of tumor
antigen by CD11c+CD11b+CD103+Ly6Chi
DCs as being critical for limiting tumor
growth through promotion of CD8+ T cell
responses (Figure 1).
In this issue of Immunity, Ma et al.
(2013) first examined the presence of
phagocytes in tumors after treatment
with CTX (the anthracyclines mitoxan-
trone or doxorubicin) and observed accu-
mulation of F4/80+CD169+ macrophages
and CD11b+Ly6G+ granulocytes 48 hr af-
ter CTX, with increases in CD11c+CD86+
DCs as early as 12 hr posttreatment. Early
accumulation of DCs was driven by ATP
release because no increase in myeloidcells was observed when neoplastic cells
were transfected with the ecto-ATPase
CD39 or when tumors were transplanted
into mice lacking the purinergic receptor
P2Y2, known to direct monocyte chemo-
taxis toward apoptotic cells (Chekeni
et al., 2010).
To addresswhethermyeloid cell infiltra-
tion was driven by enhanced recruitment,
altered differentiation, or both, the authors
first evaluated total leukocyte presence
following CTX. Whereas no kinetic differ-
ence in reconstitution by CD45.2+ cells
following whole-tumor transfer from
CD45.1 hosts was observed, a significant
increase in CD11b+ myeloid cells with a
CD34+c-Kit+Sca1CD16/32+ progenitor
phenotype in anthracycline-treated tu-
mors was revealed. Colony formation
was confined to theCD11b+Ly6Chi subset
of these cells, which expanded roughly 2-
fold in treated tumors and generated a
3-fold increase in colony formation on a
per-cell basis as compared to CTX-naive
controls. In vivo, Ly6Chi cells isolated
from anthracycline-treated tumors pre-
dominantly differentiated into Ly6G+
granulocytes, consistent with results from
other investigators (Youn et al., 2013). In
contrast, cells that were adoptively trans-
ferred into tumor-bearing mice treated
